A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

Inclusion criteria

• . Informed consent and assent (as applicable) per Institutional Review Board/Ethics Committee (IRB/EC)
• . Male or female subjects with a body weight ≥5 kg, who are ≥12 months and \<18 years of age at time of baseline
• . Cholestasis as manifested by total sBA ≥3× ULN (applies to primary cohort only)
• . An average AM ItchRO(Obs) score ≥1.5 during 4 consecutive weeks of the screening period, leading to the baseline visit (Visit 1)
• . Completion of at least 21 valid\* morning ItchRO(Obs) entries during 4 consecutive weeks of the screening period, leading to the baseline visit (Visit 1) (\*valid = completed and not answered as "I don't know"; maximum allowed invalid reports = 7, no more than 2 invalid reports during the last 7 days before randomization)
• . Diagnosis of PFIC based on the following:
• . Male and females of non-childbearing potential. Males and non-pregnant, non-lactating females of childbearing potential who are sexually active must agree to use acceptable methods of contraception during the study and 30 days following the last dose of the study medication. Females of childbearing potential must have a negative pregnancy test
• . Access to email or phone for scheduled remote visits

Exclusion criteria